Hyperinsulinemic euglycemic clamp is the gold standard for investigating and quantifying insulin resistance. This technique is widely used in clinics and laboratories to measure insulin action on glucose utilization in humans and animals for clinical and basic science research. Low-dose insulin infusions are more useful for assessing the response of the liver, whereas high-dose insulin infusions are useful for assessing peripheral (i.e., muscle and fat) insulin action. Incorporation of radioactive-labeled glucose during euglycemic clamps makes it possible to measure glucose metabolism in individual organs. In HDB, the mature clamp technique have been validated and actively performed in animal models of obesity, diabetes, and its complications. The study design could be tailored for our clients' specific requirements.
Fig. 11 Hyperinsulinemic euglycemic clamp in Sprague-Dawley (SD) rats. Glucose infusion rates were determinated
with insulin infusion at 3 mU/kg/min or 10 mU/kg/min.
We are excited to announce the installation and operation of SyncroPatch 384, the latest generation of automated patch clamp (APC) system which can be implemented into all phases of drug discovery.
HD Biosciences Co., Ltd. (HDB), a leading biology-focused preclinical drug discovery contract research organization (CRO), today announces its merge with WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform.